Efectividad y seguridad del ambrisentan en pacientes con hipertensión pulmonar grupo 1

Acosta Reyes, Jorge Luis; Vanegas Escamilla, Egdda Patricia; Mendoza Beltrán, Fernán; F. Díaz, Gabriel.
Bogotá; IETS; dic. 2014. 40 p. tab, ilus.
Monografía en Español | BRISA, LILACS | ID: biblio-847169

Documentos relacionados

  1. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
  2. Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis.
  3. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
  4. Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis.
  5. [Triple combination therapy with macitentan, riociguat, and selexipag in a patient with idiopathic pulmonary arterial hypertension (functional class III)].
  6. Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension.
  7. Tyvaso DPI: Drug-device characteristics and patient clinical considerations.
  8. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
  9. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective.
  10. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.